Scholarlink

<p>To evaluate the safety and feasibility of introducing retroperitoneal single-port robot-assisted radical prostatectomy (SP-RARP) by comparing a single surgeon’s initial 50 cases with 50 recent transperitoneal multiport RARP (MP-RARP) cases in a Japanese population. Consecutive non-pelvic-lymph-node-dissection RARP performed by one surgeon between December 2022 and January 2026 (50 retroperitoneal SP-RARP, 50 transperitoneal MP-RARP) were analyzed retrospectively using the Mann–Whitney U and Fisher exact tests. Age, body mass index, initial prostate-specific antigen, clinical T stage and nerve-sparing rate were comparable, but high-grade biopsy disease (grade group ≥ 3) was more frequent with SP (50% vs. 28%; P = 0.040). Operative time was 143 vs. 152 min (P = 0.055). There were no transfusions and no Clavien–Dindo grade ≥ II complications or anastomotic leaks. Rescue analgesic doses were fewer with SP (median 0 vs. 1; P = 0.011). Three-month social continence (76.0% vs. 78.0%; P = 1.00) and the positive surgical margin rate (14.0% vs. 24.0%; P = 0.31) did not differ. Length of stay was unchanged (median 9 days). During its introduction phase, the extraperitoneal SP approach was performed safely, with a significantly lower analgesic requirement; margin status and 3-month continence did not differ significantly. Larger studies with longer follow-up are required.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety and short-term outcomes during the introduction of retroperitoneal single-port robot-assisted radical prostatectomy: a single-surgeon comparison with transperitoneal multiport radical prostatectomy in a Japanese population

  • 期刊论文

  • 发表日期：

    2026年7月20日

查看全文
  • Seiya Hattori,
  • Kaisi Shimizu,
  • Reo Kotorii,
  • Yosuke Nakanishi,
  • Kazuma Miura,
  • Yuta Kaneko,
  • Ken Nakamura,
  • Yasuto Yagi,
  • Toru Nishiyama,
  • Tetsuo Momma

摘要

To evaluate the safety and feasibility of introducing retroperitoneal single-port robot-assisted radical prostatectomy (SP-RARP) by comparing a single surgeon’s initial 50 cases with 50 recent transperitoneal multiport RARP (MP-RARP) cases in a Japanese population. Consecutive non-pelvic-lymph-node-dissection RARP performed by one surgeon between December 2022 and January 2026 (50 retroperitoneal SP-RARP, 50 transperitoneal MP-RARP) were analyzed retrospectively using the Mann–Whitney U and Fisher exact tests. Age, body mass index, initial prostate-specific antigen, clinical T stage and nerve-sparing rate were comparable, but high-grade biopsy disease (grade group ≥ 3) was more frequent with SP (50% vs. 28%; P = 0.040). Operative time was 143 vs. 152 min (P = 0.055). There were no transfusions and no Clavien–Dindo grade ≥ II complications or anastomotic leaks. Rescue analgesic doses were fewer with SP (median 0 vs. 1; P = 0.011). Three-month social continence (76.0% vs. 78.0%; P = 1.00) and the positive surgical margin rate (14.0% vs. 24.0%; P = 0.31) did not differ. Length of stay was unchanged (median 9 days). During its introduction phase, the extraperitoneal SP approach was performed safely, with a significantly lower analgesic requirement; margin status and 3-month continence did not differ significantly. Larger studies with longer follow-up are required.